

CURRICULUM VITAE

Sami George Diab, M.D.

OFFICE ADDRESS:

Rocky Mountain Cancer Centers-Aurora
1700 South Potomac St.
Aurora, CO 80012
Phone: (303) 418-7600
FAX: (303) 750-3137

DATE AND PLACE OF BIRTH:

July 1, 1965, Damascus, Syria

CITIZENSHIP:

U.S. Naturalized Citizen, April 1995

EDUCATION:

1982 French School of Damascus (General Science Degree)
1988 M.D. Medical School, Damascus University, Damascus, Syria

POSTDOCTORAL TRAINING:

06/90-06/93 Internship and Residency in Internal Medicine, Wayne State University, Detroit, Michigan
07/93-07/94 Fellow in Medical Oncology/Hematology, UT M.D. Anderson Cancer Center, Houston, Texas
08/94-07/96 Fellow in Medical Oncology/hematology, University of Texas Health Science Center at San Antonio
01/03-12/05 Associate fellow-Integrative Medicine Program at the University of Arizona. Program director: Andrew Weil M.D.

HOSPITAL STAFF AND ACADEMIC APPOINTMENTS:

11/04-present Clinical assistant professor, University of Colorado Health Science Center

6/99-present Rocky Mountain Cancer Centers-Aurora,
Colorado

9/98-6/99 Chief, Medical Oncology, Audie Murphy Veterans
Hospital
San Antonio, Texas

8/96-6/99 Associate Director, Fellowship Program, Department
of Medicine, Division of Medical Oncology, The
University of Texas Health Science Center, San
Antonio, Texas

8/96-6/99 Assistant Professor, Department of Medicine, The
University of Texas Health Science Center, San
Antonio, Texas

8/96-6/99 Staff Physician, Medicine Service, Audie L. Murphy
Division, South Texas Veterans Health Care System,
Department of Veterans Affairs, San Antonio, Texas

7/99-now attending physician, Rocky Mountain Cancer Centers-
Colorado

LICENSURE AND CERTIFICATION:

1993 ABIM, Internal Medicine, #151059
1995 ABIM, Medical Oncology, #151059
1992 Michigan License, Permit #2998956
1999 Colorado License # 37758

MEMBERSHIPS:

1990 American College of Physicians
1994 American Association for Cancer Research
1998 American Association for the Advancement of
Science
1998 American Society of Clinical Oncology

COMMITTEES:

4/97-6/99 Executive Breast Committee, South West Oncology
Group

7/97-6/99 Cancer Control Committee, The University of Texas
Health Science Center at San Antonio, San Antonio,
Texas

1/98-6/99 Institutional Review Board, The University of Texas
Health Science Center at San Antonio, San Antonio,
Texas

7/96-6/99 Credentials Committee, Cancer Therapy & Research
Center,
San Antonio, Texas

7/99-now Breast cancer committee-US Oncology research program
1/02-1/03 Chairman- Institutional Review Board-Health One Alliance
1-01-now Institutional Review Board-Health One Alliance
7/05-6/07 Executive committee-Medical Center of Aurora

BENCH RESEARCH EXPERIENCE:

7/94-9/95 Molecular Biology of Estrogen Receptor: Identification of ER associated proteins using Yeast-Two-Hybrid system.

MANUSCRIPT REVIEWER:

Journal of Clinical Oncology
Breast Cancer Research and Treatment
Investigational New Drugs
Anti-Cancer Drugs
International Journal of Cancer

PUBLICATIONS:

1. **Diab SG**, Castles CG, Fuqua SAW. Role of Altered Estrogen Receptors in Breast Cancer. In Vedeckis WV, (ed.): Hormone and Cancer. Birkhauser, Boston 1996. Pp 261-281, 1996
2. **Diab SG**, Yu Y-Y, Hilsenbeck SG, Allred DC, and Elledge RM. WAF1/CIP1 Protein Expression In Human Breast Cancer. Breast Cancer Research and Treatment 43: 99-103, 1997
3. **Diab SG**, Hilsenbeck S, De Moor C, Clark GM, Osborne CK, Ravdin P, and Elledge RM. Radiation Therapy and Survival in Breast Cancer Patients with 10 or More Positive Auxiliary Lymph Nodes Treated with Mastectomy. Journal of Clinical Oncology, 16: 1655-1660, 1998
4. **Sami G. Diab**, Sharyn D. Baker, Amita Joshi, Howard A. Burris, Patrick W. Cobb, Miguel A. Villalona-Calero, S. Gail Eckhardt, Geoffrey R. Weiss, Gladys I. Rodriguez, Ronald Drenkler, Maura Kraynak, Lisa Hammond, Michael Finizio, Daniel D. Von Hoff, and Eric K. Rowinsky. A Phase I and Pharmacokinetic

Study of Losoxantrone and Paclitaxel in Patients with Advanced Solid Tumors. *Clinical Cancer Research*, 5: 299-308, 1999

5. **Diab SG**, Clark GM, Libby A, Allred DC, Osborne CK, and Elledge RM. Tumor Characteristics and Clinical Outcome of Tubular and Mucinous Breast Carcinoma. *Journal of Clinical Oncology* 17: 1442-1448, 1999
6. **Sami G. Diab**, Susan G. Hilsenbeck, Elzbieta Izbicka, Steve Weitman and Daniel D. Von Hoff. Significant Activity of a Novel Cytotoxic Agent, LY295501, Against a Wide Range of Tumors in the Human Tumor Cloning System. *Anti-Cancer Drugs*, 10: 303-307, 1999
7. Sami G. Diab, Richard M. Elledge, Gary M. Clark. Tumor Characteristics and Clinical Outcome of Elderly Patients with Breast Cancer. *Journal of the National Cancer Institute* 92, 550-556, 2000
8. Sharma S, and **Diab SG**. Are We Just Specialists or Is It Time For Us to Broaden Our Horizons in Treating The Cancer Patient? *Seminars in Oncology*. 24(5), 1997
9. Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, **Diab SG**, Hammond LA, Johnson T, Villalona-Calero M, Fraass U, Statkevich P, Von Hoff DD, Eckhardt SG. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. *Clin Cancer Res*. 1999 Jul;5(7):1629-37.
10. Hidalgo M, Villalona-Calero MA, Eckhardt SG, Drenkler RL, Rodriguez G, Hammond LA, **Diab SG**, Weiss G, Garner AM, Campbell E, Davidson K, Louie A, O'Neil JD, von Borstel R, Von Hoff DD, Rowinsky EK . Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
J Clin Oncol 2000 Jan;18(1):167-77
11. Zhao HH, Herrera RE, Coronado-Heinsohn E, Yang MC, Ludes-Meyers JH, Seybold-Tilson KJ, Nawaz Z, Yee D, Barr FG, **Diab SG**, Brown PH, Fuqua SA, Osborne CK. Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. *J Biol Chem*. 2001 Jul 27;276(30):27907-12. Epub 2001 May 15.

12. Villalona-Calero MA, Blum JL, Jones SE, **Diab S**, Elledge R, Khoury P, Von Hoff D, Kraynak M, Moczygemba J, Kromelis P, Griffin T, Rowinsky EK. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. *Ann Oncol.* 2001 May;12(5):605-14.
13. Forouzesh B, Takimoto CH, Goetz A, **Diab S**, Hammond LA, Smetzer L, Schwartz G, Gazak R, Callaghan JT, Von Hoff DD, Rowinsky EK. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies. *Clin Cancer Res.* 2003 Nov 15;9(15):5540-9
14. Mullineaux LG, Castellano TM, Shaw J, Axell L, Wood ME, **Diab S**, Klein C, Sitarik M, Deffenbaugh AM, Graw SL. Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado. *Cancer.* 2003 Aug 1;98(3):597-602
15. Laura Q.M. Chow, Derek J. Jonker, Scott A. Laurie, Justin A. Call, **Sami George Diab**, Glenwood Goss, Michelle McWilliam, Erjian Wang, Richard Chao, S. Gail Eckhardt, D. Ross Camidge. Sunitinib (SU) in combination with pemetrexed (P) in patients with advanced solid malignancies: a Phase I dose escalation study, ASCO 2008.
16. O'Bryant, Cindy; Lieu, Chris; Leong, Stephen; Boinpally, Ramesh; Basche, Michele; Gore, Lia; Leonardi, Kristin; Schultz, Mary Kay; Hariharan, Sujatha; Chow, Laura; **Diab, Sami**; Gibbs, Amy; Eckhardt, S. A dose-Ranging Study of the Pharmacokinetics and Pharmacodynamics of the Selective Apoptotic Antineoplastic Drug (SAAND), OSI-461, in Patients With Advanced Cancer, In the Fasted and Fed State.
17. Laura Q. Chow, Derek J Jonker, Scott A Laurie, Justin A. Call, Sami G. Diab, Michelle McWilliam, Glenwood D. Goss, Erjian Wang, Richard Chao, S. Gail Eckhardt, D. Ross Camidge. A phase I dose escalations study of sunitinib (SU) in combination with pemetrexed (Pem) in patients (pts) with advanced solid malignancies. 1084 ESMO April, 2008.

ORAL PRESENTATIONS AT NATIONAL AND INTERNATIONAL MEETINGS:

Radiation therapy improves survival by decreasing local failure in breast cancer patients with 10 or more positive auxiliary lymph nodes treated with mastectomy. SG Diab, CA de Moor, GM Clark, CK Osborne, PM Ravdin, RM Elledge. Meeting of the American Society of Medical Oncology, Denver, 1997

Does radiotherapy have an impact on systemic relapse. G Clark, SG Diab, S Hilsenbeck. Presented at the 20th International Congress of Chemotherapy. Sydney, Australia, 7/97.

Lobular Carcinoma in Situ: Incidence of subsequent ipsilateral and contralateral invasive cancer. San Antonio Breast Cancer Symposium 2004.

ABSTRACTS::

2006

A phase 1 study of Belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors and lymphoma

CL O'Bryant, S Leong, DR Camidge, DL Gustafson, L Gore, J Call, S Diab, J Spratlin, JA Zwiebel, SG Eckhardt; University of Colorado Cancer Center, Aurora, CO, USA; NCI Cancer Therapy Evaluation Program, Bethesda, MD, USA.

A Dose-Ranging Study of the Toxicities, Pharmacological, and Biological Effects of the Selective Apoptotic Antineoplastic Drug (SAAND), OSI-461, in Patients With Advanced Cancer, in the Fasting and Fed State. CH Lieu, S Leong, M Basche, L Gore, K Leonardi, MK Schultz, S Hariharan, L Chow, **S Diab**, A Gibbs, R Boinpally, SG Eckhardt, CL O'Bryant. University of Colorado Cancer Center, Aurora, CO, USA; OSI Pharmaceuticals, Inc, Boulder, CO, USA. 2005

A FIRST IN HUMAN DOSE-RANGING STUDY TO ASSESS THE PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICITIES OF THE MEK

INHIBITOR, ARRY-142886 (AZD6244), IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES. LQM Chow, SG Eckhardt, J Reid, J Molina, L Hanson, J Piens, S Hariharan, M Basche, L Gore, **S Diab**, C O'Bryant, S Grolnic, B Hippert, MP Doyle, L Maloney, G Gordon, S Brown, K Litwiler, G Poch, AA Adjei. University of Colorado Cancer Center, Aurora, CO; Mayo Clinic, Rochester, MN; Array BioPharma, Boulder, CO. 2005

Rapid Increase in Serum VEGF in Cancer Patients Treated with IMC-1121B, a Human IgG1 Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Monoclonal Antibody. Deshan Yu³, Floyd Fox³, Camidge DR¹, Eckhardt SG¹, **Diab S**¹, Gore L¹, Temmer E², Cohen RB², Hagop Youssoufian³, Eric Rowinsky³; ¹University of Colorado Cancer Center, Aurora, CO; ²Fox Chase Cancer Center, Philadelphia, PA; ³ImClone Systems Incorporated, Branchburg, NJ.

A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer R. B. Cohen, D. R. Camidge, S. Diab, L. Gore, L. Chow, C. O'Bryant, E. Temmer, F. Fox, H. Youssoufian, S. G. Eckhardt; University of Colorado Cancer Center, Denver, CO; Fox Chase Cancer Center, Philadelphia, PA; ImClone Systems Incorporated, Branchburg, NJ

A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs) **S. Diab**, SG Eckhardt, A. Tan, G Frenette, W. Depinto, Grippo, M. DeMario (submitted to ASCO 2007)

A phase I study of weekly R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced cancer

S. Leong, SG Eckhardt, S. Moulder, T. Warren, L. Gore, **S. Diab**, M. Kurman, C. Dias, G. Greig, R. Kurzrock; University of Colorado Cancer Center, Aurora, CO; M.D. Anderson Cancer Center, Houston, TX; Hoffmann-La Roche Inc., Nutley, NJ. (submitted to ASCO 2007)

Annual San Antonio Breast Cancer Symposium 1996 and 1997

Diab SG, deMoor CA, Clark GM, Elledge RM. Adjuvant Local Radiation Therapy and Survival in Breast Cancer Patients with 10 or More Positive Lymph Nodes. Presented at the 19th Annual San Antonio Breast Cancer Symposium, 1996

Diab SG*, Clark GM, Libby A, Allred DC, Osborne CK, and Elledge RM. Tumor Characteristics and Clinical Outcome of Tubular and Mucinous Breast Carcinoma. Presented at the 20th Annual San Antonio Breast Cancer Symposium, 1997

Annual San Antonio Breast Cancer Symposium 2003

Estrogen receptor status in ductal carcinoma in situ and subsequent invasive breast cancer.

American Society of Clinical Oncology meeting, 1997

SG Diab, CA de Moor, GM Clark, CK Osborne, PM Ravdin, RM Elledge. Radiation therapy improves survival by decreasing local failure in breast cancer patients with 10 or more positive auxiliary lymph nodes treated with mastectomy. (oral presentation).

SG Eckhardt, Y Atkins, SS Agarwala, J Eckardt, S. Diab, M Dugan, P Reidenberg, P Statkevich, M Kraynak, DD Von Hoff and EK with Cisplatin (CDDP) in Patients with Advanced Cancer. Cancer Therapy and Research Center, San Antonio, TX, University of Pittsburgh, Pittsburgh, PA and Schering-Plough, Kenilworth, NJ.

American Society of Clinical Oncology meeting, 1998

S Diab, C Britten, G Eckhardt, L Hammond, R Elledge, L Siu, S Sharma, M Hidalgo, C Aylesworth, B Razvillas, M Kraynak, S Baker, R Smith, S Averbuch, D Von Hoff, and E Rowinsky: Phase I and Pharmacokinetic (PK) Study of the Nonpolyglutamated Thymidylate Synthase (TS) Inhibitor ZD9331 Given as a 30 Minute Infusion Every 3 Weeks. Cancer Therapy and Research Center, University of Texas Health Science Center, Brooke Army Medical Center, San Antonio, TX and Zeneca Pharmaceuticals, Wilmington, DE. (poster discussion)

P Khoury, M Villalona-Calero, J Blum, S Diab, R Elledge, M Kraynak, J Moczygamba, P Kromelis, I Morales, C Brown, T Griffin, D Von Hoff, E Rowinsky: Phase I Study of Capecitabine in Combination with Paclitaxel in Patients with Previously Treated Metastatic Breast Cancer. The University of Texas Health Science Center and Cancer Therapy & Research Center, San Antonio, TX, PRN Research, Dallas TXS, and Hoffman-La Roche LTD. Nutley, New Jersey.

L Hammond, M Villalona-Calero, SG Eckhardt, R Drengler, C Aylesworth, T Johnson, M Hidalgo, G Rodriguez, S Diab, P Monroe, D Thornton, D Von Hoff, and E Rowinsky. A Phase I and Pharmacokinetic (PK) Study of the Multitargeted Antifol (MTA) LY231514 with Folic Acid. Cancer Therapy and Research Center and Brooke Army Medical Center, San Antonio, TX and Eli Lilly Company, Indianapolis, IN. Presented at the American Society of Clinical Oncology Meeting, 1998

10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 1998

S Diab, SD Baker, L Hammond, M Villalona-Calero, SG Eckhardt, C Tin-U, G Weiss, M Kraynak, C Aylesworth, L Smith, G Rodriguez, R Drengler, R Patil, L Siu, M Rothenberg, L Smetzer, E Nyhart, AM Sorniolo, D Von Hoff, and E Rowinsky. Phase I and Pharmacokinetic (PK) Study of the Diarylsulfonylurea LY295501 Administered as a single oral dose weekly for 3 weeks every 4 weeks. Cancer Therapy and Research Center, University of Texas Health Science Center, Brooke Army Medical Center, San Antonio, TX; Eli Lilly and Company, Indianapolis, IN

M Villalona-Calero, J Blum, S Diab, R Elledge, P Khoury, M Kraynak, J Moczygemba, P Kromelis, K Impellizeri, T Griffin, D Von Hoff, E rowinsky. Phase I Study of Capecitabine in Combination with Paclitaxel in Patients with Previously Treated Metastatic Breast Cancer. Cancer Therapy and Research Center, San Antonio, TX, PRN Research, Dallas TX, and Hoffman-LaRoche, Nutley, NJ

L Hammond, SD Baker, M Villalona-Calero, SG Eckhardt, R Drengler, C Aylesworth, T Johnson, M Hidalgo, G Rodriguez, S Diab, P Monroe, D Thornton, R Johnson, D Von Hoff, and E Rowinsky. A Phase I and Pharmacokinetic (PK) Study of the Multitargeted Antifol (MTA) LY231514 with Folic Acid (FA). Cancer Therapy and Reserach Center and Brooke army Med Center, San Antonio TX, and Eli Lilly Companym Inidanapolis, IN

M Hidalgo, MA Villalona-Calero, C Britten, L Siu, R Drengler, L Hammond, S Diab, E Campbell, A Louie, J O'Neil, D Von Hoff, and E Rowinsky. A Phase I and Pharmacokinetic (PK) Study of PN401 as a Rescue Agent for Escalating Doses of 5-Fluorouracil (5-FU) in Patients (PTS) with Cancer. Cancer Therapy and Reserach Center, San Antonio TX, and Pro-Neuron, Inc., Gaithesburg, MD., to be presented at 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, June 16-19, 1998

CD Britten, EK Rowinsky, SS Agarwala, SD Baker, J Eckardt, S Diab, M Dugan, P Reidenberg, P Statkevich, A Marco, A Loomba, K Forral, M Kraynak, DD Von Hoff, and SG Eckhardt. A Phase I Safety and Pharmacokinetic (PK) Study of Temozolomide in Combination with Cisplatin. Cancer Therapy and Research Center, San Antonio TX, University of Pittsburgh, Pittsburgh PA, and Schering-Plough, Kenilworth NJ

SG Diab, RM Elledge, and GM Clark. Favorable biological characteristics and clinical outcome in elderly patients with invasive ductal carcinoma (IDC) of the breast. (poster discussion) American Society of Clinical Oncology meeting, 1999

W Tan, C. Tin-U, M Villalona, L Ochoa, M Kalidas, R Drengler, P Khoury, T Herman, A W Vally, B Brady, E Rowinsky, S Diab. Phase I study of weekly paclitaxel in combination with daily cisplatin and radiation in locally advanced head and neck and non-small cell lung carcinoma and esophageal carcinoma. American Society of Clinical Oncology meeting, 1999

R Sun Young, SG Diab, C Britten, G Eckhardt, L Hammond, R Elledge, L Siu, S Sharma, M Hidalgo, C Aylesworth, B Razvillas, M Kraynak, S Baker, R Smith, S Averbuch, D Von Hoff, and E Rowinsky. Determination of the Variables affecting the Clearance of the Novel Thymidylate Synthase (TS) Inhibitor ZD9331 American Society of Clinical Oncology meeting, 1999

E Rowinsky, T Johnson, C Geyer, SG Eckhardt, L Smetzer, J Coyle, R Drengler, S Diab, R De Jager, and D Von Hoff. DX-8951f, a hexacyclic captothecin (CPT) analog on a daily x 5 schedule: a phase I and pharmacokinetic study.

T Johnson, L Hammond, R Johnson, R Drengler, SG Eckhardt, J neumanitis, M Villalona, T Williams, S Diab, J Walling, C Simmon, D Von Hoff, and E Rowinsky. Phase I and pharmacokinetic study of the multitargeted Antifol LY231514 (MTA) in combination with irinotecan (CPT-11).

MISCELLANEOUS MEETINGS:

Andersen J, Shelly C, Diab S. Receptor-Independent Augmentation of Cytokine-Induced Endothelial Cell Tissue Factor Production by Flavone Acetic Acid may Promote Vascular Thrombosis. Presented at the American Society of Hematology Meeting, 1991

Andersen J, Shelly C, Diab S. Flavone Acetic Acid Augments Cytokine-Stimulated Endothelial Cell Tissue Factor Production by a Receptor-Independent Mechanism. Presented at Symposium on the Molecular Biology of Endothelial Cells, Keystone, 1992

Diab S, Shelly C, Andersen J. Cytokine-Stimulated Human Endothelial Cells Bind IGG from Patients with Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS). Presented at American Collage of Physicians National Meeting, 1992

Diab SG, deMoor CA, Clark GM, Elledge RM. Prognostic Factors in Breast Cancer Patients with 10 or more Positive Lymph Nodes. Abstract. Presented at 5th Annual Symposium on Cancer Research, San Antonio, 1995

CL O'Bryant, S Leong, DR Camidge, L Gore, S Diab, DL Gustafson, J Call, J Spratlin, JA Zwiebel, SG Eckhardt; University of Colorado Cancer Center, Aurora, CO, USA; Colorado State University, Fort Collins, CO, USA; NCI Cancer Therapy Evaluation Program, Bethesda, MD, USA.